Trial Profile
A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions
- 28 Sep 2022 Status changed from active, no longer recruiting to completed.
- 28 Oct 2021 Interventional study model changed from single group assignment to sequential assignment.
- 20 Jul 2021 Planned End Date changed from 1 Apr 2021 to 1 Apr 2022.